Walgreens, a well-known drugstore chain in the U.S. since 1901, has faced significant challenges in recent years. The company, which went public in 1927 and later merged with the UK-based Boots to form Walgreens Boots Alliance (WBA) in 2014, has seen its stock decline and announced the closure of approximately 2,000 stores, with 450 more expected to shut down soon. This year, Walgreens faced a lawsuit by the U.S. Department of Justice over opioid-related allegations, leading to the suspension of its quarterly dividend. Additionally, WBA’s retail sales in the U.S. dropped by 4.6% in the first quarter of 2025 compared to the previous year due to inflation and reduced consumer spending. In response, WBA is nearing a deal with private equity firm Sycamore Partners to take Walgreens private for around $10 billion. Sycamore is expected to pay between $11.30 and $11.40 per share. If finalized, Sycamore will acquire WBA’s U.S. retail business, including Walgreens and Duane Reade, while potentially selling or keeping other brands public. The deal could be completed as soon as Thursday, barring any delays. — news from TheStreet